Bausch + Lomb Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Brent Saunders

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	1.2yrs
CEO ownership	n/a
Management average tenure	1.1yrs
Board average tenure	2yrs

Recent management updates

Recent updates

CEO

Brent Saunders (53 yo)

1.2yrs

Tenure

Mr. Brenton L. Saunders, J. D., also known as Brent, is CEO & Chairman of the Board at Bausch & Lomb Incorporated since 2023. He is CEO & Chairman of the Board at Bausch + Lomb Corporation since March 06,...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Osama Eldessouky	Executive VP & CFO	2.3yrs	US$6.15m	0.0048% $ 335.3k
Yehia Hashad	Executive VP of Research & Development and Chief Medical officer	2.3yrs	US$2.91m	0.0032% $ 228.5k
Brenton L. Saunders	CEO & Chairman	1.2yrs	no data	no data
Alan Waterhouse	Executive VP and Chief Supply Chain & Operations Officer	1.3yrs	no data	no data
Frederick Munsch	Senior VP	no data	no data	0.0011% $ 80.8k
A. Robert Bailey	Executive VP & Chief Legal Officer	1.1yrs	no data	0.0086% $ 606.7k
Jonathon Kellerman	Chief Compliance Officer	less than a year	no data	no data
T.J. Crawford	Chief Communications Officer	less than a year	no data	no data
Manisha Narasimhan	Chief Corporate Development & Digital Officer	less than a year	no data	no data
Asli Gevgilili	Executive VP & Chief Human Resources Officer	less than a year	no data	no data
Andrew Stewart	President of Global Pharmaceuticals & International Consumer	1.3yrs	no data	0.0020% $ 142.0k
Luc Bonnefoy	President of Surgical	no data	no data	0.00077% $ 54.1k

1.1yrs

Average Tenure

53yo

Average Age

Experienced Management: BLCO's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Brenton L. Saunders	CEO & Chairman	1.2yrs	no data	no data
Richard De Schutter	Independent Director	no data	US$287.07k	0.0040% $ 281.2k
Thomas Ross	Lead Independent Director	1.2yrs	US$362.51k	0.0036% $ 250.3k
John Paulson	Independent Director	2.1yrs	US$277.28k	0.0038% $ 269.9k
Sarah Kavanagh	Independent Director	2.1yrs	US$293.19k	0.0016% $ 116.0k
Brett Icahn	Independent Director	1.9yrs	US$244.80k	0.0038% $ 265.0k
Russel Robertson	Independent Director	2.1yrs	US$286.63k	0.0021% $ 145.5k
Andrew von Eschenbach	Independent Director	2.1yrs	US$280.95k	0.0036% $ 250.3k
Karen Ling	Independent Director	less than a year	no data	no data
Nathalie Bernier	Independent Director	2.1yrs	US$282.14k	0.0050% $ 352.2k
Gaoxiang Hu	Independent Director	1.9yrs	US$253.27k	0.0038% $ 265.0k

2.0yrs

Average Tenure

66yo

Average Age

Experienced Board: BLCO's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.

Bausch + Lomb Management

Management criteria checks 0/4

Key information

Recent management updates

Bausch + Lomb Corporation, Annual General Meeting, May 29, 2024

High number of new directors

Bausch + Lomb Corporation Announces Board Changes

Bausch + Lomb Corporation Announces Executive Changes

Bausch + Lomb Corporation Announces Executive Changes

Bausch + Lomb Corporation Announces Board Appointments, Effective March 6, 2023

Recent updates

Bausch + Lomb Corporation Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes

Bausch + Lomb Corporation to Report Q1, 2024 Results on May 01, 2024

Bausch + Lomb Corporation, Annual General Meeting, May 29, 2024

High number of new directors

Bausch + Lomb Corporation Announces Board Changes

Full year 2023 earnings released: US$0.74 loss per share (vs US$0.017 profit in FY 2022)

Bausch + Lomb Corporation Provides Earnings Guidance for the Year 2024

Bausch + Lomb Corporation to Report Q4, 2023 Results on Feb 21, 2024

Bausch + Lomb Corporation Receives FDA Approval for TENEO Excimer Laser Platform for Myopia and Myopic Astigmatism LASIK Vision Correction Surgery

New major risk - Financial position

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.051 loss in 3Q 2022)

Bausch + Lomb Corporation Raises Revenue Guidance for the Full Year of 2023

Bausch + Lomb Will Present New Scientific Data and Analyses At American Academy of Ophthalmology Annual Meeting

Bausch + Lomb Corporation to Report Q3, 2023 Results on Nov 01, 2023

Bausch + Lomb Corporation Launches LUMIFY EYE ILLUMINATIONS in the United States

Bausch + Lomb Corporation Launches MIEBO (Perfluorohexyloctane Ophthalmic Solution) in the United States

Second quarter 2023 earnings released: US$0.091 loss per share (vs US$0.014 profit in 2Q 2022)

Bausch + Lomb Corporation Announces Executive Changes

Now 22% undervalued

Bausch + Lomb Corporation to Report Q2, 2023 Results on Aug 02, 2023

Bausch + Lomb Corporation (NYSE:BLCO) agreed to acquire Blink® product line of eye and contact lens drops of Johnson & Johnson Vision for approximately $110 million.

Bausch + Lomb Corporation (NYSE:BLCO) signed an agreement to acquire ophthalmology assets from Novartis AG (SWX:NOVN) for $2.5 billion.

Bausch + Lomb Launches PreserVision AREDS 2 Formula Soft Gels Plus CoQ10 in the United States

Bausch + Lomb Corporation to Present the Results of 11 Scientific Poster Presentations Inviding the Company's Consumer, Vision Care and Pharmaceutical Products

Bausch + Lomb Corporation Launches Biotrue Hydration Boost Contact Lens Rehydrating Drops in the United States

Bausch + Lomb Corporation Launches Bausch + Lomb Infuse®? Multifocal Silicone Hydrogel Contact Lenses in the United States

Bausch + Lomb Corporation Announces Executive Changes

Bausch + Lomb Corporation and Novaliq Announce Fda Approval of Miebo™? (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease

First quarter 2023 earnings released: US$0.26 loss per share (vs US$0.057 profit in 1Q 2022)

Bausch + Lomb Corporation Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released

Now 20% undervalued

Bausch + Lomb Corporation Announces Board Appointments, Effective March 6, 2023

Bausch + Lomb and Modulight Announces FDA Approval of ML6710i Photodynamic Laser

Bausch + Lomb Corporation, Annual General Meeting, Apr 24, 2023

Bausch + Lomb Corporation to Report Q4, 2022 Results on Feb 22, 2023

Bausch + Lomb Corporation (NYSE:BLCO) acquired AcuFocus, Inc.

Bausch + Lomb Corporation Announces the U.S. Introduction of Preservision® AREDS 2 Formula Mini Soft Gels with OCUSorb™

Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology

Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology

Bausch + Lomb Corporation Enters into CEO Separation Agreement with Joseph C. Papa

Bausch + Lomb Corporation Receives 510(k) Clearance from FDA for Biotrue® Hydration Boost Contact Lens Rehydrating Drops

Third quarter 2022 earnings released

Bausch + Lomb Corporation Revises Revenue Guidance for the Year 2022

Bausch + Lomb Corporation Announces Introduction of Project Watson Health Care Products for Dogs in the United States

Bausch + Lomb Corporation to Report Q3, 2022 Results on Nov 02, 2022

Bausch + Lomb Corporation Introduces Enhanced Ocuvite® Adult 50+ Eye Vitamin Formulation with Vitamin D

Bausch + Lomb and Novaliq GmbH Announces U.S. FDA Filing Acceptance for Investigational Treatment NOV03 (Perfluorohexyloctane)

Second quarter 2022 earnings released: EPS: US$0.014 (vs US$0.13 in 2Q 2021)

Bausch + Lomb Corporation Reaffirms Earnings Guidance for the Full Year 2022

Bausch + Lomb Corporation Enrolls First Patient in Lasik Clinical Trial Evaluating Use of Technolas® Teneo™ Excimer Laser* for Vision Correction Surgery for Hyperopia with Astigmatism

Bausch + Lomb Corporation to Report Q2, 2022 Results on Aug 04, 2022

Bausch + Lomb Corporation Announces Joseph C. Papa Has Stepped Down as Chair of the Board

Bausch + Lomb Corporation and Novaliq GmbH Announce Submission of New Drug Application for Investigational Treatment Nov03 (Perfluorohexyloctane)

Bausch + Lomb Corporation Announces Appointment of Brett Icahn and Gary Hu to its Board of Directors

Investor sentiment deteriorated over the past week

Bausch + Lomb Corporation Provides Earnings Guidance for the Full Year 2022

Bausch + Lomb Corporation Announces Scientific Data on Latest Biotrue® Products to Be Presented At American Optometric Association's Optometry's Meeting

Bausch + Lomb Corporation to Report Q1, 2022 Results on Jun 08, 2022

Bausch + Lomb Receives Health Canada Approval of Lumify(R) Redness Reliever Eye Drops

First quarter 2022 earnings released: EPS: US$0.057 (vs US$0.077 in 1Q 2021)

Bausch + Lomb Corporation Released Findings from Survey Designed to Gain an Understanding of Retina Specialists

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure